The pharmacological and biological importance of EZH2 signaling in lung cancer

Entezari, Maliheh; Taheriazam, Afshin; Paskeh, Mahshid Deldar Abad; Sabouni, Eisa; Zandieh, Mohammad Arad; Aboutalebi, Maryam; Kakavand, Amirabbas; Rezaei, Shamin; Hejazi, Elahe Sadat; Saebfar, Hamidreza; Salimimoghadam, Shokooh; Mirzaei, Sepideh; Hashemi, Mehrdad; Samarghandian, Saeed

doi:10.1016/j.biopha.2023.114313

Cited by 12 publications

(4 citation statements)

References 219 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Through suppressing transcription of mesenchymal genes, EZH2 induces mesenchymal to epithelial transition and then tumor colonization in NSCLC (79). The pharmacological values of EZH2 in NSCLC has been reviewed, recently (80).…”

Section: Discussionmentioning

confidence: 99%

EZH2: A Critical Competing Endogenous RNA in Cancer Research - A Scoping Review

Salehi-Mazandarani,

Mahmoudian-Hamedani,

Farajzadegan

et al. 2024

Preprint

View full text Add to dashboard Cite

In recent years, research on the competing endogenous RNAs (ceRNAs) in cancer is in full swing. These investigations are discovering the importance of critical RNAs in cancer progression. Enhancer of zeste 2 polycomb repressive complex 2 subunit (EZH2) is one of these RNAs that has been identified as a potential therapeutic target in many types of cancer. Up to now, many studies have been conducted to elucidate ceRNA role of EZH2 in cancer. Due to EZH2's dual role as an oncogene and tumor suppressor in cancer, a more thorough exploration of its ceRNA functions may enhance clinical approaches to cancer treatment. In the current scoping review, we searched online databases including PubMed, Web of Science, Scopus, Embase, Cochrane Library, and Google Scholar to identify experimentally-validated ceRNA axes including EZH2 in human cancers. We identified 62 unique axes consisting of 30 microRNAs (miRNAs), 31 long non-coding RNAs (lncRNAs), 9 messenger RNAs (mRNAs), and 14 circular RNAs (circRNAs). Notably, SPRY4-IT1 - miR-101-3p - EZH2 and XIST - miR-101-3p - EZH2 were recurrent axes observed in multiple cancer types. Among the most frequent miRNAs were miR-101-3p, miR-144-3p, and miR-124-3p, and ceRNAs including SPRY4-IT1, XIST, SNHG6, HOXA11-AS, MALAT1, and TUG1 emerged as frequent competitors of EZH2 for miRNA binding. This scoping review highlights the prevalence and diversity of EZH2-containing ceRNA axes in cancer, suggesting their potential as therapeutic targets. Future research should delve deeper into these axes to elucidate their functional significance and assess their clinical applicability.

show abstract

Section: Discussionmentioning

confidence: 99%

EZH2: A Critical Competing Endogenous RNA in Cancer Research - A Scoping Review

Salehi-Mazandarani,

Mahmoudian-Hamedani,

Farajzadegan

et al. 2024

Preprint

View full text Add to dashboard Cite

show abstract

“…This modification leads to the silencing of its target genes (Duan et al, 2020). Activation of EZH2 increases the proliferation rate of lung cancer cells (Entezari et al, 2023), promotes metastasis and EMT resulting in lung cancer progression. Elevated EZH2 levels and an increased count of genes silenced via H3K27me3 were linked to the advanced stage of lung cancer (Agarwal et al, 2016).…”

Section: Epigenetic Profilementioning

confidence: 99%

Significance of extracellular vesicles in orchestration of immune responses in Mycobacterium tuberculosis infection

Alipoor,

Elieh-Ali-Komi

2024

Front. Cell. Infect. Microbiol.

View full text Add to dashboard Cite

Mycobacterium tuberculosis (M.tb), the causative agent of Tuberculosis, is an intracellular bacterium well known for its ability to subvert host energy and metabolic pathways to maintain its intracellular survival. For this purpose, the bacteria utilize various mechanisms of which extracellular vehicles (EVs) related mechanisms attracted more attention. EVs are nanosized particles that are released by almost all cell types containing active biomolecules from the cell of origin and can target bioactive pathways in the recipient cells upon uptake. It is hypothesized that M.tb dictates the processes of host EV biogenesis pathways, selectively incorporating its molecules into the host EV to direct immune responses in its favor. During infection with Mtb, both mycobacteria and host cells release EVs. The composition of these EVs varies over time, influenced by the physiological and nutritional state of the host environment. Additionally, different EV populations contribute differently to the pathogenesis of disease at various stages of illness participating in a complex interplay between host cells and pathogens. These interactions ultimately influence immune responses and disease outcomes. However, the precise mechanisms and roles of EVs in pathogenicity and disease outcomes remain to be fully elucidated. In this review, we explored the properties and function of EVs in the context of M.tb infection within the host microenvironment and discussed their capacity as a novel therapeutic strategy to combat tuberculosis.

show abstract

“…Common histone methyltransferases associated with ncRNAs in digestive system tumors include EZH2, RIZ1, and LSD1. EZH2 is often overexpressed or mutated in cancer, and it silences some tumor suppressor genes by methylating H3K27 to H3K27me3 28 . H3K27 is a lysine residue and the 27th amino acid of histone H3 29 .…”

Section: Methyltransferasesmentioning

confidence: 99%

The bidirectional interplay between ncRNAs and methylation modifications in gastrointestinal tumors

Kong,

Yu,

Guo

et al. 2023

Int. J. Biol. Sci.

View full text Add to dashboard Cite

The aberrant expression of methylation and ncRNAs, two crucial regulators of epigenetic modifications, has been widely demonstrated in cancer. The complex interplay between them is essential in promoting malignant phenotype, poor prognosis, and drug resistance in GI tumors (including esophageal, gastric, colorectal, liver, and pancreatic cancers). Therefore, we summarize the interrelation process between ncRNAs and methylation modifications in GI tumors, including the detailed mechanism of methylation enzyme regulation of ncRNAs, the molecular mechanism of ncRNAs regulation of methylation modifications, and the correlation between the interactions between ncRNAs and methylation modifications and clinical features of tumors. Finally, we discuss the potential value of ncRNAs and methylation modifications in clinical diagnosis and therapy.

show abstract

The pharmacological and biological importance of EZH2 signaling in lung cancer

Cited by 12 publications

References 219 publications

EZH2: A Critical Competing Endogenous RNA in Cancer Research - A Scoping Review

EZH2: A Critical Competing Endogenous RNA in Cancer Research - A Scoping Review

Significance of extracellular vesicles in orchestration of immune responses in Mycobacterium tuberculosis infection

The bidirectional interplay between ncRNAs and methylation modifications in gastrointestinal tumors

Contact Info

Product

Resources

About